Navigation Links
Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients.  Over the past 6 years, UCB has awarded more than 200 scholarships, totaling over $1 million, to people whose lives have been directly affected by epilepsy, including those with epilepsy, their caregivers and family members.  Epilepsy is a common neurological condition that can affect anyone at anytime.  In the United States, 1 in 100 people are living with epilepsy.

"It is inspiring to see that year after year UCB recognizes the dreams of people affected by epilepsy and supports these individuals in accomplishing their academic aspirations," said Brien Smith, MD, Henry Ford Hospital, Neurology.

This year, 40 recipients were selected from a pool of nearly 800 applicants. UCB awarded 30 scholarships to people living with epilepsy and 10 scholarships to family members or caregivers of someone living with epilepsy.  Each recipient will receive a scholarship of $5,000 for tuition at colleges, graduate schools and technical schools across the country.  Applicants were considered based on their application, personal essay, letters of recommendation and their determination to live beyond the boundaries of epilepsy.

This year's recipients will be honored on the UCB Family Epilepsy Scholarship Facebook page.  To see photos and quotes from the 2010 recipients, read updates from past scholarship recipients and learn more about the UCB Family Epilepsy Scholarship Program™, please go to Facebook.com/UCBEpilepsyScholarship.  

2010 Scholarship Recipients and Their Selected Learning Institution:Emerald Allen

Concordia Lutheran UniversityKamell Ean Alston

West Chester UniversityCourtney Barringtine

Howard UniversityBeth Barton

Roosevelt UniversityAshley Breedlove

Midwestern State UniversityTravis Brown

Bowling Green Technical CollegeDalton Burghardt

California State University ChicoMadeleine Clifton

James Madison UniversityErin Cline

Glen Oaks Community CollegeDanielle DellaVella

Whitworth UniversityKristen Emerson

University of ConnecticutKaren Escobedo

University of California RiversideTanya Evans

Youngstown State UniversitySamuel Fazioli

Northeastern UniversityClaire Fons

University of Wisconsin MilwaukeeDai Quan Garner

Wesley CollegeDeborah Gunn

National UniversityCarrie Harpole

Henderson Community CollegePaul Anthony Henderson Jr.

University of South CarolinaAndrew Hibbitt

Florida Gulf Coast UniversityEmma Himpelmann

Kendall CollegeAaron Hoover

University of Southern IndianaEliza Jacobs-Brichford

Ithaca CollegeKatherine Japp

University of Texas, BrownsvilleAmanda Johnson

University of Pittsburgh Shelley Kays

Community College of MorrisTim Kelly

Central Michigan UniversityHannah Nicole Lawrence

Hinds Community CollegeMaureen Mahon

St. Louis UniversityEmmanuel Marrero

University of ToledoAmanda Mills

Goldey-Beacom CollegeLaKeisha Parnell

Atlanta Christian CollegeAshlin Phelps

Whitworth UniversityChristian Profitt

Midway CollegeAllison Rapsas

American Musical and Dramatic Academy Patrick Sheeran

George Mason UniversityKaitlyn Votel

St. Catherine UniversityLauren Wilson

Seattle UniversitySelena Winter

Adelphi UniversityAbout Epilepsy Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and three million people in the U.S.—making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Roughly 20-30 percent of people living with epilepsy have either uncontrolled seizures or significant side effects secondary to medication. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit www.EpilepsyAdvocate.com.

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

The UCB Family Epilepsy Scholarship Program™ is a trademark of the UCB group of companies.

Further InformationAndrea LevinSenior Manager, Communications & PR, CNS, UCB, Inc.T 770.970.8352M 404.483.7329Andrea.Levin@ucb.comLaura FinleyCooney/Waters GroupT 212.886.2258LFinley@cooneywaters.com
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
3. Cypin Production Announces Launch of U.S./China BioPharma Conference:
4. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
5. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
7. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
8. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
9. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
11. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):